Mazdutide

Mazdutide (IBI362, LY3305677) is an investigational dual GLP-1/glucagon receptor agonist developed by Innovent Biologics and Eli Lilly. It is one of the leading 'dual agonist' weight-loss drugs targeting both GLP-1 (for appetite reduction) and glucagon (for energy expenditure). It is approved in China for type 2 diabetes and chronic weight management and is in late-stage trials elsewhere. Research-grade material is sold strictly for laboratory use.

Mazdutide is one of the next-generation weight-loss peptides built on the GLP-1 framework that made semaglutide famous, but with a twist: it also activates the glucagon receptor. Glucagon normally raises blood sugar but also boosts metabolic rate. By combining appetite reduction with metabolic activation, mazdutide aims for greater weight loss than single-target GLP-1 drugs.

Mazdutide activates both the GLP-1 receptor (reducing appetite, slowing gastric emptying, improving insulin secretion) and the glucagon receptor (increasing energy expenditure and hepatic glucose handling). Balancing both requires careful ratio engineering — too much glucagon activity raises blood sugar undesirably.

• •Type 2 diabetes (DREAMS trials in China)
• •Obesity and chronic weight management
• •Cardiometabolic outcomes
• •Comparative dual-agonist pharmacology
• •Non-alcoholic fatty liver disease (NAFLD)

Mazdutide is a rising star in weight-loss forums alongside tirzepatide and retatrutide. Threads focus on early clinical data (significant weight loss with NAFLD improvements), the first-in-China approval pathway, and its place in the dual/triple agonist arms race.

“GLP-1 with built-in metabolic acceleration.”

Typically used as monotherapy in trials. Stacking with other appetite or metabolic compounds is not a published protocol.

Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent and Eli Lilly, approved in China for diabetes and weight management. It combines appetite reduction with increased energy expenditure.